Status:

RECRUITING

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Lead Sponsor:

Wuhan Createrna Science and Technology Co., Ltd

Conditions:

Paroxysmal Nocturnal Haemoglobinuria (PNH)

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.

Detailed Description

This is a multi-center, randomized, open-label, active comparator-controlled, parallel group study. The purpose of this study is to determine whether MY008211A compared to eculizumab is efficacious an...

Eligibility Criteria

Inclusion

  • Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%.
  • Mean hemoglobin level \<100 g/L at screening.
  • LDH \> 1.5 x Upper Limit of Normal (ULN) at screening.
  • Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.

Exclusion

  • Patients with reticulocytes \<100x10\^9/L; platelets \<30x10\^9/L; neutrophils \<0.5x10\^9/L.
  • History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.
  • Known or suspected hereditary complement deficiency.
  • Previous bone marrow or hematopoietic stem cell transplantation.
  • Previous splenectomy.
  • A history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.

Key Trial Info

Start Date :

August 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2025

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT06932744

Start Date

August 30 2024

End Date

December 30 2025

Last Update

May 9 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China, 100032

2

Chinese Academy of Medical Sciences Hematology Hospital

Tianjin, Tianjin Municipality, China, 300020